

IN THE CLAIMS

Please amend the claims as follows:

1-35. (Canceled)

36. (Previously Presented) An apparatus comprising:

an implantable device including a substantially cylindrical insulating exterior peripheral surface of an elongate intravascular lead body having a proximal end and a distal end and the peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating initially providing a slippery lubricating surface after being exposed to an aqueous substance, and then later providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing tissue ingrowth.

37. (Previously Presented) The apparatus of claim 36, the lead including at least one elongate electrical conductor in the insulating body.

38. (Previously Presented) The apparatus of claim 37, in which a distal portion of the lead is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein.

39. (Previously Presented) The apparatus of claim 36, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

40. (Previously Presented) The apparatus of claim 39, in which the non-therapeutic agent includes mannitol.

41. (Previously Presented) The apparatus of claim 39, in which the non-therapeutic agent includes glycerol.

42. (Previously Presented) The apparatus of claim 36, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

43. (Previously Presented) The apparatus of claim 42, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

44. (Previously Presented) The apparatus of claim 36, in which the coating includes particles disposed in a water-vapor permeable medium.

45. (Currently Amended) An apparatus comprising:

an implantable device including a substantially cylindrical insulating exterior peripheral surface of an elongate intravascular lead body having a proximal end and a distal end and the peripheral surface that is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing tissue ingrowth.[[.]]

46. (Previously Presented) The apparatus of claim 45, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

47. (Previously Presented) The apparatus of claim 45, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

48. (Previously Presented) The apparatus of claim 47, in which the non-therapeutic agent includes mannitol.

49. (Previously Presented) The apparatus of claim 47, in which the non-therapeutic agent includes glycerol.

50. (Previously Presented) The apparatus of claim 45, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

51. (Previously Presented) The apparatus of claim 50, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

52. (Previously Presented) The apparatus of claim 45, in which the coating includes particles disposed in a water-vapor permeable medium.

53. (Currently Amended) An apparatus comprising:

an implantable device including [[a]] an insulating exterior peripheral surface of an elongate intravascular lead body having a proximal end and a distal end and the peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating including a therapeutic agent disposed in a medium that is permeable by water vapor.

54. (Previously Presented) The apparatus of claim 53, in which the coating provides at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the at least one of the rough and the porous surface allowing adhesive but breakable tissue ingrowth.

55. (Previously Presented) The apparatus of claim 54, in which the coating initially provides a slippery lubricating surface after being exposed to an aqueous substance, and then later provides the at least one of the rough surface and the porous surface after being exposed to the aqueous substance.

56. (Previously Presented) The apparatus of claim 53, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

57. (Previously Presented) The apparatus of claim 56, in which a distal portion of the lead is sized and shaped to be inserted into at least one of a coronary sinus and a great cardiac vein.

58. (Previously Presented) The apparatus of claim 53, in which coating includes a therapeutic agent and a non-therapeutic agent, and in which the therapeutic agent has a different release rate than the non-therapeutic agent.

59. (Previously Presented) The apparatus of claim 58, in which the non-therapeutic agent includes mannitol.

60. (Previously Presented) The apparatus of claim 58, in which the non-therapeutic agent includes glycerol.

61. (Previously Presented) The apparatus of claim 53, in which the coating includes a first therapeutic agent and a second therapeutic agent that is different from the first therapeutic agent.

62. (Previously Presented) The apparatus of claim 61, in which the first therapeutic agent has a different release rate than the second-therapeutic agent.

63. (Previously Presented) An apparatus comprising:

an implantable device including a substantially cylindrical insulating exterior peripheral surface of an elongate intravascular lead body having a proximal end and a distal end and the peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the coating including two therapeutic agents with different release rates.

64. (Previously Presented) The apparatus of claim 63, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

65. (Previously Presented) The apparatus of claim 63, in which the two therapeutic agents include at least one of dexamethasone acetate and dexamethasone sodium phosphate.

66. (Previously Presented) The apparatus of claim 63, in which the coating further includes at least one of mannitol and glycerol.

67. (Previously Presented) An apparatus comprising:

an implantable device including a substantially cylindrical insulating exterior peripheral surface of an elongate intravascular lead body having a proximal end and a distal end and the peripheral surface; and

an at least partially dissolvable coating at least partially on a portion of the peripheral surface of the device body, the coating providing at least one of a rough surface and a porous surface after being exposed to the aqueous substance, the coating including at least one therapeutic agent and at least one lubricating agent.

68. (Previously Presented) The apparatus of claim 67, in which the implantable device includes a lead, the lead including:

an insulating elongate body having a proximal end and a distal end and the peripheral surface; and

at least one elongate electrical conductor in the insulating body.

69. (Previously Presented) The apparatus of claim 67, in which the at least one therapeutic agent includes dexamethasone.

70. (Previously Presented) The apparatus of claim 67, in which the at least one therapeutic agent includes dexamethasone sodium phosphate.

71. (Previously Presented) The apparatus of claim 67, in which the at least one lubricating agent includes mannitol.

72. (Previously Presented) The apparatus of claim 67, in which the at least one of the rough surface and the porous surface allows enough tissue ingrowth to affix an intravascular lead, and the tissue ingrowth is modified by the at least one therapeutic agent to allow the intravascular lead to be easily intravascularly extracted by breaking the tissue ingrowth.